Abstract：
BACKGROUND: Hidradenitis suppurativa (HS) is a painful, debilitating, and poorly understood condition, which is suboptimally diagnosed, managed, and treated. Evidence supporting various treatment modalities is sparse.
OBJECTIVE: To incorporate scientific evidence and expert opinions to develop useful guidance for the evaluation and management of patients with HS.
METHODS: An expert panel of Canadian dermatologists and surgeons developed statements and recommendations based on available evidence and clinical experience. The statements and recommendations were subjected to analysis and refinement by the panel, and voting was conducted using a modified Delphi technique with a prespecified cutoff agreement of 75%.
RESULTS: Ten specific statements and recommendations were accepted by the expert panel. These were grouped into 4 domains: diagnosis and assessment, treatment and management, comorbidities and a multidisciplinary approach, and education.
CONCLUSIONS: These statements and recommendations will serve to increase awareness of HS and provide a framework for decisions involving diagnosis and management. Evidence suggests that antibacterial and anti-tumour necrosis factor therapies are effective in the treatment of HS. This is supported by the clinical experience of the authors. Further clinical research and the establishment of multidisciplinary management teams will continue to advance management of HS in Canada.
OBJECTIVE: To incorporate scientific evidence and expert opinions to develop useful guidance for the evaluation and management of patients with HS.
METHODS: An expert panel of Canadian dermatologists and surgeons developed statements and recommendations based on available evidence and clinical experience. The statements and recommendations were subjected to analysis and refinement by the panel, and voting was conducted using a modified Delphi technique with a prespecified cutoff agreement of 75%.
RESULTS: Ten specific statements and recommendations were accepted by the expert panel. These were grouped into 4 domains: diagnosis and assessment, treatment and management, comorbidities and a multidisciplinary approach, and education.
CONCLUSIONS: These statements and recommendations will serve to increase awareness of HS and provide a framework for decisions involving diagnosis and management. Evidence suggests that antibacterial and anti-tumour necrosis factor therapies are effective in the treatment of HS. This is supported by the clinical experience of the authors. Further clinical research and the establishment of multidisciplinary management teams will continue to advance management of HS in Canada.
摘要：
背景：化脓性汗腺炎（HS）是一种痛苦的，衰弱，和对病情知之甚少，诊断欠佳，管理，和治疗。支持各种治疗方式的证据很少。
目的：纳入科学证据和专家意见，为HS患者的评估和管理提供有用的指导。
方法：加拿大皮肤科医生和外科医生专家小组根据现有证据和临床经验制定了声明和建议。小组对声明和建议进行了分析和完善，并且使用改良的Delphi技术进行投票，预设的截止协议为75％。
结果：专家小组接受了10项具体声明和建议。这些被分为4个领域：诊断和评估，治疗和管理，合并症和多学科方法，和教育。
结论：这些声明和建议将有助于提高对HS的认识，并为涉及诊断和管理的决策提供框架。证据表明，抗菌和抗肿瘤坏死因子疗法可有效治疗HS。作者的临床经验支持了这一点。进一步的临床研究和多学科管理团队的建立将继续推进加拿大的HS管理。
目的：纳入科学证据和专家意见，为HS患者的评估和管理提供有用的指导。
方法：加拿大皮肤科医生和外科医生专家小组根据现有证据和临床经验制定了声明和建议。小组对声明和建议进行了分析和完善，并且使用改良的Delphi技术进行投票，预设的截止协议为75％。
结果：专家小组接受了10项具体声明和建议。这些被分为4个领域：诊断和评估，治疗和管理，合并症和多学科方法，和教育。
结论：这些声明和建议将有助于提高对HS的认识，并为涉及诊断和管理的决策提供框架。证据表明，抗菌和抗肿瘤坏死因子疗法可有效治疗HS。作者的临床经验支持了这一点。进一步的临床研究和多学科管理团队的建立将继续推进加拿大的HS管理。
